With biosimilars entering the FDA licensure process this year, the surrounding discussion has moved from the theoretical to the practical. Drawing on data from PP&P’s 2015 Generics survey (pppmag.com/genericdrugs), interesting trends are developing in pharmacy’s approach to these products. Pharmacy directors considering these products as candidates for formulary review are now in the majority and notably, both clinical data and price are cited as key decision points in formulary assessments.